stars 1 stars 2 stars 3

GENOMIC VISION develops novel diagnostic and drug discovery solutions based on its world-leading nanotechnology for DNA analysis in the areas of cancer and acute diseases. These diagnostic tests and drug discovery tools operate where genome dynamics and human disease intersect. GENOMIC VISION uses a powerful technique, Molecular Combing Technology, for the direct visualization of single DNA molecules to detect quantitative and qualitative changes in the genome landscape and establish their contribution to pathology. GENOMIC VISION initial focus is towards early cancer detection and drug therapy monitoring. The company possesses an unrivalled capability for discovering genomic biomarkers implicated in the predisposition and development of many forms of cancer and in following and analyzing DNA replication during cell division. This provides a unique approach for evaluating the efficacy of new drugs on the cell cycle.

Genomic Vision Questions

The Genomic Vision annual revenue was $7 million in 2026.

Laurence Maggiorella is the Scientific Director of Genomic Vision.

12 people are employed at Genomic Vision.

Genomic Vision is based in Bagneux, Ile-de-France.

The NAICS codes for Genomic Vision are [621, 62151, 6215, 325, 62, 32].

The SIC codes for Genomic Vision are [283, 80, 28, 807].

G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users